DRUG - DEVICE COMBINATION PRODUCTS: COMPARATIVE REGULATORY PATHWAYS IN THE UNITED STATES AND INDIA

A new dynamic in medical product development and regulatory approval was brought about by drug-device combo products. and business interactions that offer insightful insights for the creation of new combo product generations. With their promise for novel treatments, combination products which combine pharmaceuticals, biologics, and medical equipment have completely changed the healthcare industry. Every healthcare product in the pharmaceutical sector is divided into three categories: drugs, devices, and biologics. Each of these categories is governed by a different regulatory authority department. This article explores the complex world of safety, efficacy, and regulatory issues related to combination products.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-05-01
DOI
https://doi.org/10.5281/zenodo.19881776
Primary Topic
Pharmaceutical Economics and Policy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

DRUG - DEVICE COMBINATION PRODUCTS: COMPARATIVE REGULATORY PATHWAYS IN THE UNITED STATES AND INDIA

Prajakta Balakshe2 Ketaki Umesh Shalgaonkar1*
Zenodo (CERN European Organization for Nuclear Research)
Pharmaceutical Economics and Policy
article

DRUG - DEVICE COMBINATION PRODUCTS: COMPARATIVE REGULATORY PATHWAYS IN THE UNITED STATES AND INDIA

Prajakta Balakshe2 Ketaki Umesh Shalgaonkar1*
article en

Abstract

A new dynamic in medical product development and regulatory approval was brought about by drug-device combo products. and business interactions that offer insightful insights for the creation of new combo product generations. With their promise for novel treatments, combination products which combine pharmaceuticals, biologics, and medical equipment have completely changed the healthcare industry. Every healthcare product in the pharmaceutical sector is divided into three categories: drugs, devices, and biologics. Each of these categories is governed by a different regulatory authority department. This article explores the complex world of safety, efficacy, and regulatory issues related to combination products.

Zenodo (CERN European Organization for Nuclear Research)
Industry, innovation and infrastructure
Openalex Percentile: Top 3%
Pharmaceutical Economics and Policy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.